Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Press Release
DNTH212 (BDCA2 and BAFF/APRIL) Licensing Webcast Oct 16, 2025 8:00 AM EDT Webcast Supporting Materials Licensing of DNTH212 (BDCA2 and BAFF/APRIL) from Leads Biolabs 1.9 MB
